A decision by the Pennsylvania Supreme Court regarding whether it will hear the appeal involving two Risperdal lawsuits is awaited which can further impact hundreds of Risperdal lawsuits currently pending under the centralized MDL litigation in Philadelphia. Both the cases were filed in 2014 and were dismissed by the Philadelphia Court of Common Pleas granting the defendants Johnson & Johnson and its Janssen Pharmaceuticals’ motion for summary judgment after it was brought to the court’s notice that the statute of limitations on the claims had expired in 2009.
Two coordinated actions have been filed for Risperdal cases: one in Los Angeles Superior Court (Risperdal and Invega Product Liability Cases, JCCP 4775) and the other in Philadelphia (In re: Risperdal Litigation, March 2010 Term, Case No. 100300296).
